TMS for Symptom Reduction in Schizophrenia
Neuroimaging studies suggest that aberrant activities at specific brain regions such as sensory areas and language-related areas are related to psychosis symptoms including auditory and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has been approved by FDA for treatment of depression. Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry. Among psychotic symptoms, there are preliminary significant improvement in treatments of auditory hallucination using TMS with small samples, but those treatments are not robust in larger samples. The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients. We aim to develop a TMS treatment method with a fMRI-defined treatment target area, where the TMS target is individually identified to maximize the TMS effects. The identification method uses both the anatomical character and its functional relationship with auditory hallucination and other psychosis symptoms. If the current target-identification successfully identified effective TMS target individually, the treatment efficacy will be significant improved and more patients will benefit from TMS treatment.
- Schizophrenia and Related Disorders
- Eligible Ages
- Between 21 Years and 62 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Male and Female between ages 21-62
- Ability to give written informed consent (age 21 or above)
- For patient participants, Evaluation to Sign Consent (ESC) 10 or greater.
- Medication stability for 4 weeks (same drugs at same dosages)
- Any history of seizures
- Any Family history of epilepsy in first degree relatives
- Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
- Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.
- Taking > 400 mg clozapine/day
- Failed TMS screening questionnaire
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth,that cannot be safely removed.
- History of head injury with loss of consciousness over 10 minutes; history of brain surgery
- Can not refrain from using alcohol and/or marijuana 24 hours or more & cigarette smoking half and hour or more prior to experiments.
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self report; or by positive pregnancy test)
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Double (Participant, Outcomes Assessor)
Active rTMS stimulation
|Real active rTMS stimulation.||
Sham rTMS stimulation
|Sham repetitive TMS stimulation.||
- University of Maryland, Baltimore
Study ContactXiaoming Du, PhD